Pancreatic Cancer is under clinical development by Innovative Cellular Therapeutics and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pancreatic Cancer’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Recommended Buyer's Guides
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pancreatic Cancer overview
The therapeutic candidate is under development for the treatment of pancreatic cancer. It comprises of T-cells genetically engineered to express chimeric antigen receptors targeting tumor-associated antigen (TAA) expressing cells. It is being developed based on CoupledCAR platform technology.
Innovative Cellular Therapeutics overview
Innovative Cellular Therapeutics (ICT) is a biotechnology company that disovers and develops cellular immunotherapies for the treatment of cancer. ICT is headquartered in Shanghai, China.
For a complete picture of Pancreatic Cancer’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
